KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash from Operations (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Cash from Operations data on record, last reported at 77700000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 197.25% year-over-year to 77700000.0; the TTM value through Dec 2025 reached 170600000.0, up 190.63%, while the annual FY2025 figure was 170600000.0, 190.63% up from the prior year.
  • Cash from Operations reached 77700000.0 in Q4 2025 per EBS's latest filing, up from 2300000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 328100000.0 in Q4 2021 and bottomed at 184000000.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 15455000.0, with a median of 1400000.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: plummeted 831.37% in 2022, then soared 197.25% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 328100000.0 in 2021, then tumbled by 71.72% to 92800000.0 in 2022, then crashed by 65.41% to 32100000.0 in 2023, then tumbled by 348.91% to 79900000.0 in 2024, then skyrocketed by 197.25% to 77700000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 77700000.0 in Q4 2025, 2300000.0 in Q3 2025, and 106400000.0 in Q2 2025.